Úvod > Novinky a Tlačové správy (anglicky)

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
TRIBUTE study shows superiority of Chiesi’s Trimbow® (Beclometasone...
Chiesi completed a long-term clinical study with its extrafine fixed-dose triple combination inhaler (Trimbow®) in a single pressurised metered dose inhaler (pMDI) for COPD...
Chiesi Group reports an increased turnover in 2016 and consolidates its global presence
Glybera▼ (alipogene tiparvovec) in Europe
For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study.
GOLD 2017 Report: Chiesi Farmaceutici highlights relevant gaps
Chiesi Enhances Asthma Portfolio with Acquisition of Atopix Therapeutics
The Italian Prime Minister Matteo Renzi, has visited Chiesi Farmaceutici Research Center in Parma